Peru-1 5 (AVANT).
Peru-15 is a single dose, recombinant cholera vaccine under development by AVANT Immunotherapeutics for the potential prevention of cholera. A phase II trial of Peru-15 was ongoing in June 2003, and as of September 2003 AVANT was planning a phase III trial in a developing country, and phase IIb and phase III challenge studies in travelers.
Jones
Taff
T
ID Biomedical Corp of Quebec, 7150 Frederick Banting, Montreal H4S 2A1, Quebec, Canada tjones@idbiomedical.com
D002626:Chemistry, Pharmaceutical; D022121:Cholera Vaccines / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D010330:Patents as Topic; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D022121:Cholera Vaccines; C497037:Peru 15; D014614:Vaccines, Synthetic